CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for BRISTOL MYERS SQUIBB CO (BMY)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for BMY, mapped to public ticker BMY (CIK 0000014272). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingBMY35% conf

BRISTOL MYERS SQUIBB CO (BMY) — PHASE3 protocol updated 11 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →